Citadel Advisors
RANI icon

Citadel Advisors’s Rani Therapeutics RANI Stock Holding History

Citadel Advisors’s Portfolio RANI Stock Details RANI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$12K Sell
15,800
-260,800
-94% -$231K ﹤0.01% 13481
2026
Q1 		$203K Buy
276,600
+63,100
+30% +$80.6K ﹤0.01% 11395
2025
Q4 		$288K Buy
+213,500
New +$322K ﹤0.01% 10234
2025
Q3 		– Sell
-14,000
Closed -$7.2K – 13855
2025
Q2 		$7.2K Sell
14,000
-7,300
-34% -$5.96K ﹤0.01% 12219
2025
Q1 		$26.8K Buy
21,300
+18,000
+545% +$26.6K ﹤0.01% 12915
2024
Q4 		$4.52K Buy
3,300
+800
+32% +$1.68K ﹤0.01% 13925
2024
Q3 		$5.4K Buy
2,500
+500
+25% +$1.43K ﹤0.01% 13494
2024
Q2 		$7.6K Sell
2,000
-5,400
-73% -$28K ﹤0.01% 13237
2024
Q1 		$23K Buy
+7,400
New +$25.4K ﹤0.01% 12914
2023
Q3 		– Sell
-3,200
Closed -$13.2K – 14960
2023
Q2 		$13.2K Buy
3,200
+2,200
+220% +$10.2K ﹤0.01% 13049
2023
Q1 		$5.16K Buy
+1,000
New +$6.01K ﹤0.01% 13888

Other funds holding RANI

SB
Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
AIC
AWM Investment Company New York $1.15B AUM 201.65% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
LP
Longaeva Partners Chicago, Illinois $4.58B AUM 43.91% 1-Year Est. Return
PAMP
Polar Asset Management Partners Toronto, Ontario, Canada $6.07B AUM 34.81% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
HCM
Heights Capital Management San Francisco, California $433M AUM 8.59% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Citadel Advisors's RANI Position: Q2 2026 in Review

Citadel Advisors opened a new position in Rani Therapeutics (RANI) in Q2 2026: 641,995 shares worth $488K. The stake represents ﹤0.01% of the portfolio and ranks #9926 among its holdings. This is a return to the name: Citadel Advisors previously reported a position in RANI as recently as Q3 2025.

Citadel Advisors first reported a position in RANI in Q1 2023 and has held it in 9 quarters since. 68 funds tracked by Wall St. Rank hold RANI as of Q2 2026.

  • Citadel Advisors held 641,995 shares of Rani Therapeutics worth $488K as of Q2 2026.
  • Rani Therapeutics was a new Citadel Advisors position in Q2 2026.
  • Rani Therapeutics made up ﹤0.01% of Citadel Advisors's portfolio in Q2 2026, its #9926 holding.
  • Citadel Advisors first reported a position in Rani Therapeutics in Q1 2023 and has held it in 9 quarters since.
  • 68 funds tracked by Wall St. Rank held Rani Therapeutics as of Q2 2026.

Based on Citadel Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.